Serum Interleukin (IL)-9 and IL-10, but not T-Helper 9 (Th9) Cells, are Associated With Survival of Patients With Acute-on-Chronic Hepatitis B Liver Failure.
Serum Interleukin (IL)-9 and IL-10, but not T-Helper 9 (Th9) Cells, are Associated With Survival of Patients With Acute-on-Chronic Hepatitis B Liver Failure.
复制标题
DOI：
10.1097/md.0000000000003405
复制
发表时间：
2016-04
期刊：
影响因子：
1.6
通讯作者：
Su Z
中科院分区：
文献类型：
--
作者：
Yu X;Zheng Y;Deng Y;Li J;Guo R;Su M;Ming D;Lin Z;Zhang J;Su Z
据报道，CD 4 + T辅助（Th）细胞对于启动和维持针对B型肝炎病毒（HBV）感染的有效免疫应答是必需的。Th 9细胞是产生白细胞介素（IL）-9和IL-10的新的CD 4 + Th细胞亚群。本研究旨在研究外周血中Th 9细胞相对于CD 4+细胞数量的百分比。我们还检测了HBV感染不同阶段血清IL-9和IL-10水平及其与肝病进展和预后的关系。收集111例HBV感染者的全血标本，其中慢性B型肝炎（CH B）39例，HBV合并肝硬化（HBV-LC）25例，慢加急性肝衰竭（ACLF）21例，健康对照26例。检测Th 9细胞百分率及血清IL-9、IL-10水平。Th 9细胞百分比和血清IL-9、IL-10水平在各组间差异无统计学意义，也与B e抗原状态、肝硬化并发症、炎症指标及预后指标无关。CHB患者抗病毒治疗前后Th 9细胞百分比无变化。Th 9细胞与ACLF患者的生存率无相关性。然而，与存活的ACLF患者相比，未存活的ACLF患者的IL-9和IL-10水平显著较高。此外，基线IL-9水平预测ACLF患者预后的敏感性为87.5%，特异性为61.5%。因此，我们的数据表明，Th 9细胞不太可能参与HBV感染的发病机制，但IL-9和IL-10的升高可能是ACLF预后不良的信号。
CD4+ T helper (Th) cells are reported to be essential for initiating and maintaining an effective immune response to hepatitis B virus (HBV) infection. Th9 cells are a new subset of CD4+ Th cells that produce interleukin (IL)-9 and IL-10. The present study aimed to investigate the percentage of Th9 cells relative to the number of CD4+ cells in peripheral blood. We also measured serum IL-9 and IL-10 levels in different stages of HBV infection and their relationship with progress and prognosis of liver disease. Whole blood samples from 111 patients with HBV infection, including 39 chronic hepatitis B (CHB), 25 HBV-liver cirrhosis (HBV-LC), 21 acute-on-chronic liver failure (ACLF) patients, and 26 healthy controls were collected. The percentage of Th9 cells and serum IL-9 and IL-10 levels were determined. There was no significant difference in the percentage of Th9 cells and serum IL-9 and IL-10 levels among different groups, nor were these related to hepatitis B e antigen status, complications of cirrhosis, inflammation index, or prognosis indexes. There was no change in the percentage of Th9 cells before and after antiviral treatment in CHB patients. There was no correlation of Th9 cells with survival of ACLF patients. However, IL-9 and IL-10 levels were significantly higher in the nonsurvived ACLF patients compared to survived ACLF patients. Furthermore, baseline IL-9 level predicted the prognosis of ACLF patients with 87.5% sensitivity and 61.5% specificity. Thus, our data indicate that Th9 cells were unlikely involved in the pathogenesis of HBV infection, but elevation in IL-9 and IL-10 may signal poor prognosis for ACLF.